Effect of sitagliptin combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in early diabetic nephropathy

BACKGROUND Early diabetic nephropathy(DN)is a complication of diabetes mellitus.It mainly affects kidney microvessels and glomerular function,and its timely and effective treatment is critical for early DN.However,the effects of treatments comprising simple Western medicine are not optimal.With the promotion and implementation of integrated Chinese and western medicine treatments,remarkable results have been achieved for many diseases.To this end,we explored the clinical efficacy of integrated traditional Chinese and western medicines for the treatment of early DN.AIM To investigate the effect of sitagliptin tablets combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in patients with early DN.METHODS Through a retrospective analysis,123 patients with early DN were admitted to the endocrinology clinic of the Changzhou NO.7 People’s Hospital from January 2021 to October 2022 and were selected as study subjects.After rigorous screening,100 patients with early DN were enrolled.The control group(CG,n=50)and the observation group(OG,n=50)were divided according to the treatment method.The CG were treated with sitagliptin,and the OG were treated with sitagliptin plus the Yiqi yangyin huoxue decoction.Both groups were treated for 3 mo.For both groups,the baseline data and clinical efficacy were compared,and changes in blood glucose levels,lipid levels,renal function,and hematological indicators before(T0)and after(T1)treatment were assessed.RESULTS The total effective rate for the OG was 94.00%and that of the CG was 80.00%(P<0.05).After treatment(T1),the levels of fasting blood glucose,2 h postprandial glucose,total cholesterol,triacylglycerol,and low-density lipoprotein cholesterol in OG patients were obviously lower than those in the CG(P<0.05),and cystatin C,homocysteine,urinary microalbumin,and blood creatinine values in OG patients were also obviously lower than those in the CG(P<0.05);erythrocyte deposition,plasma viscosity,whole blood high shear viscosity,and whole blood low shear viscosity were markedly lower in OG patients than in the CG(P<0.05).CONCLUSION Sitagliptin combined with Yiqi yangyin huoxue decoction has a remarkable effect when used to treat patients with early DN.Further,it is helpful in improving hemorheological indices and controlling disease progression.

Knowledge Attitude and Practice of General Physicians for Early Detection of Diabetic Nephropathy in Cotonou

Introduction: General physicians can play an important role in the early detection of diabetic nephropathy (DN). Purpose: To assess the levels of general physicians’ knowledge, attitude and practice in terms of early detection of DN in Cotonou. Method: It was a cross-sectional, analytical and descriptive study which was conducted from 1st March 2015 to 30th September 2015. Every general physician working in a health structure in Cotonou who consented to participate in the study was included. We did not included medical specialists and general physicians working in nephrology department. Data were collected through a survey form designed with a score to assess the various items such as: knowledge, attitude and practice. The significance threshold is set to below 0.05. Results: In total, 202 general physicians were included. The average age was 30.9 ± 6.9 years ranging from 24 to 68 years. A male predominance was observed with 2.2 sex ratio. The majority of respondent medical physicians had poor knowledge in 76.2% cases, bad attitudes (61%) and bad practices (64.9%) in terms of early detection of diabetic nephropathy. There was positive impact of continuing medical training focused on diabetic nephropathy on attitudes (p = 0.016) and practices (p = 0.001) of these physicians. Conclusion: Diabetic nephropathy requires particular attention. General physicians’ continuous training is a principal solution.

Significance of intensive glycemic control on early diabetic nephropathy patients with microalbuminuria

Objective To investigate the therapeutic effect of intensive glycemic control on patients with early diabetic nephropathy. Methods A total of 41 type 2 diabetes patients who developed microalbuminuria were divided into two groups randomly. Patients in Group A received intensive glycemic control and the blood glucose in Group B was regularly controlled. Glycemic monitoring and control were followed for 12 weeks to observe the changes of microalbuminuria in both groups; meanwhile the levels of serum lipids and coagulation indices were also recorded. Results The urine albumin excretion rate (UAER) in Group A decreased significantly from (47.91±13.86)mg/24h to (35.31±14.56)mg/24h after 12 weeks (P<0.05),and this decrease was significantly greater than that in Group B. However,Group B had no significant difference in UAER decrease [(48.93±13.32)mg/24h to (40.48±19.62)mg/24h,P>0.05]. The decrease of triglyceride (TG) and low-density lipoprotein cholesterol (LDL cholesterol),and the increase of high-density lipoprotein cholesterol (HDL cholesterol) showed no significant differences (P>0.05). And the level of plasma fibrinogen (FIB) showed no significant decrease after 12 weeks,either (P>0.05). Conclusion Intensive glycemic control reduces the level of microalbuminuria and may ameliorate the progression of early diabetic nephropathy.

Protective effect of calcium dobesilate combined with benazepril therapy on renal injury in patients with early diabetic nephropathy and the possible molecular mechanisms

Objective:To explore the protective effect of calcium dobesilate combined with benazepril therapy on renal injury in patients with early diabetic nephropathy and the possible molecular mechanisms.Methods:A total of 50 patients with early diabetic nephropathy treated in our hospital between May 2012 and January 2016 were collected, and according to the random number table, the patients were divided into observation group (n=25) and control group (n=25). On the basis of conventional treatment, control group of patients received benazepril therapy, observation group of patients received calcium dobesilate combined with benazepril therapy, and the treatment lasted for 3 months. Before and after treatment, automatic biochemical analyzer was used to detect the levels of renal injury indexes in peripheral blood, RIA method was used to detect the levels of renal injury indexes in urine, ELISA method was used to detect the levels of renal fibrosis indexes and Western-blot method was used to detect the protein expression of TGF-β1/BMP-7 and Smad signaling pathway molecules in renal tissue. Results: Before treatment, differences in renal injury index levels, renal fibrosis index levels and signaling pathway molecule protein expression were not statistically significant between two groups of patients. After treatment, BUN, SCr andβ-TP levels in the peripheral blood as well as KIM-1 level in urine of observation group were lower than those of control group;renal fibrosis indexes TGF-β1, CTGF, TIMP-1, LN and HA levels in serum of observation group were lower than those of control group;TGF-β1 and Smad2/3 protein expression in renal tissue of observation group were lower than those of control group while Smad7 and BMP-7 protein expression were higher than those of control group.Conclusion: Calcium dobesilate combined with benazepril therapy can reduce the renal injury and inhibit the fibrosis process in patients with early diabetic nephropathy, and it achieves the above effect by regulating the TGF-β1/BMP-7 and Smad signaling pathway function.

Evaluation of renal function and oxidative stress after adjuvant epalrestat treatment of early diabetic nephropathy

Objective:To explore the influence of adjuvant epalrestat treatment of early diabetic nephropathy on renal function and oxidative stress.Methods:A total of 80 patients with early diabetic nephropathy who were treated in our hospital between January 2013 and February 2016 were collected and divided into observation group and control group according to single-blind parallel control. Control group of patients received routine therapy, and observation group of patients received adjuvant epalrestat treatment on this basis. After 8 weeks of treatment, automatic biochemical analyzer was used to detect the renal function indexes of two groups of patients;RIA method was used to detect the serum renal fibrosis index levels;enzyme-linked immunosorbent assay (ELISA) was used to detect serum oxidative stress index levels.Results:Before treatment, differences in serum renal function, renal fibrosis and oxidative stress index levels were not statistically significant between two groups of patients;after 8 weeks of treatment, serum renal function indexes Scr, BUN, CysC andβ2-MG levels of observation group were lower than those of control group, renal fibrosis indexes CⅣ, CTGF and TGF-β1 levels were lower than those of control group, oxidation indexes ROS, LHP and AOPPs levels were lower than those of control group, anti-oxidation indexes SOD, VitE, VitC and T-AOC levels were significantly higher than those of control group, and the differences were statistically significant.Conclusion:Adjuvant epalrestat therapy can optimize the renal function and reduce the systemic oxidative stress response in patients with early diabetic nephropathy.

Assessment of renal function and oxidative stress after alprostadil combined with valsartan treatment of early diabetic nephropathy

Objective:To analyze the renal function and oxidative stress after alprostadil combined with valsartan treatment of early diabetic nephropathy.Methods:A total of 230 patients with early diabetic nephropathy who were treated in our hospital between December 2011 and December 2015 were divided into control group (n=115) and observation group (n=115) according to random number table. Control group received valsartan treatment, observation group received alprostadil combined with valsartan treatment, and both lasted for one month. After treatment, renal blood flow parameters were evaluated by ultrasound contrast technique, renal function index levels in peripheral blood and urine were measured, and serum levels of oxidative stress indexes were detected.Results:After 1 month of treatment, area under curve (AUC) and time to peak (TTP) levels under ultrasound contrast of observation group were lower than those of control group while derived peak intensity (DPI) level was higher than that of control group;peripheral blood urea nitrogen (BUN) and serum creatinine (Scr) levels of observation group were lower than those of control group, albumin (Alb) level was higher than that of control group, and urine red blood cell (RBC) level was lower than that of control group;serum oxidative stress indexes malondialdehyde (MDA) and advanced oxidation protein products (AOPP) levels of observation group were lower than those of control group while superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) levels were higher than those of control group.Conclusion: Alprostadil combined with valsartan can optimize renal function and reduce systemic oxidative stress in patients with early diabetic nephropathy.

Assessment of the renal function, peroxidation damage and inflammatory injury after epalrestat combined with alprostadil treatment of early diabetic nephropathy

Objective:To study the renal function, peroxidation damage and inflammatory injury after epalrestat combined with alprostadil treatment of early diabetic nephropathy.Methods:90 patients with early diabetic nephropathy treated in our hospital between June 2011 and November 2015 were collected and divided into observation group and control group (n=45) according to the single-blind randomized control method. Observation group received epalrestat combined with alprostadil treatment, control group received alprostadil treatment alone, and the treatment of both groups lasted for 3 months. Before treatment and after 3 months of treatment, turbidimetric immunoassay was used to detect the renal function indexes in peripheral blood, rate method was used to detect the renal function indexes in urine, and ELISA method was used to detect the levels of peroxidation indexes and inflammation indexes.Results:Before treatment, differences in renal function, peroxidation damage and inflammatory damage indexes were not statistically significant between two groups of patients (P>0.05). After 3 months of treatment, creatinine (Scr), cystatin C (CysC),β2 microglobulin (β2-MG), N-acetyl-β-D-glucosaminidase (NAG), reactive oxygen species (ROS), advanced protein oxidation products (AOPPs), interleukin-8 (IL-8), interleukin-27 (IL-27) and procalcitonin (PCT) levels of observation group were lower than those of control group while catalase (CAT), total superoxide dismutase (TSOD), interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-13 (IL-13) levels were higher than those of control group (P<0.05). Conclusions:Epalrestat combined with alprostadil can protect the renal function and inhibit the peroxidation damage and inflammatory injury in patients with early diabetic nephropathy.

Effects of Irbesartan combined Atorvastatin on serum levels of Cys C, Hcy, TNF-α, ET, TGF-b1 in patients with early diabetic nephropathyn

Objective: To observe the effects of Irbesartan combined with Atorvastatin on early diabetic nephropathy patients' serum Cys C, Hcy, TNF-α, ET and TGF-b1 levels. Methods: A total of 60 early diabetic nephropathy patients were randomly divided into observation group (30 cases) and control group (30 cases). Observation group: Irbesartan combined with Atorvastatin;control group: patients were treated only by Irbesartan. Recording and comparing the levels of Cys C, Hcy, TNF-α, ET and TGF-b1 before and after treatment. Results: (1) Before treatment, there was no statistically significant difference in the serum FBG, TG, Scr, BUN levels between the two groups. After treatment, compared with the same group before treatment, the serum TG, Scr, BUN levels of the two groups were significantly lower, and those levels of observation group were significantly better than the control group, the difference between two groups was statistically significant;(2) Before treatment, there was no statistically significant difference in the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels between the two groups. After treatment, compared with the same group before treatment, the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels of the two groups were significantly lower, and those levels of observation group were significantly better than the control group, the difference between two groups was statistically significant. Conclusion: Irbesartan combined with Atorvastatin for early diabetic nephropathy patients can reduce the levels of serum Cys C, Hcy, TNF-α, ET, TGF-b1 and be beneficial to protect their nephritic function.

THE VALUE OF URINE PROTEIN EXCRETION IN DIAGNOSING EARLY DIABETIC NEPHROPATHY

We tested urine albumin excretion rate (UAER), urine transrerrin (TRF ), retinolulnding protein (RBP), N --acetyl--aD-gi ucosamlnldase (N AG ), P, - mi c rogl obu I in (P, -- M G ) and lgGIn 45 cases of NIDDM. Thirty cases with UAER<300 mg/d were divided into two groups. Data wereshown with urine protein index (urine protein/urine creatlne). ResultS showed that urine transferrinwas more seusltlve than albumlu, and the combined test or urine Protein is nontraumatic, which hadsteatncance to diagnose early diabetic nepkropatby.

Lipocalin-2 as a biomarker for diabetic nephropathy

Diabetes is a major global public health issue.The prevalence of type 1 diabetes is comparatively static,as hereditary and genetic causes are involved,while type 2 diabetes(T2D)prevalence is increasing day by day.T2D is associated with chronic complications,including diabetic neuropathy(DN),nephropathy,retinopathy,and other complications like diabetic foot.DN is the main complication of both types of diabetes.DN can be diagnosed by routine laboratory tests,microalbuminuria>300 mg/24 h,and a gradual decrease in glomerular filtration rate.As the appearance of microalbuminuria is a late manifestation,an early marker for renal damage is needed.Lipocalin-2,also known as neutrophil gelatinaseassociated lipocalin(NGAL),is a small protein purified from neutrophil granules and a good marker for kidney disease.NGAL is a transporter protein responsible for many physiological processes,such as inflammation,generation of the immune response,and metabolic homeostasis.NGAL has been reported to depict the early changes in renal damage when urine microalbumin is still undetecable.Therefore,elucidating the role of NGAL in detecting DN and understanding its mechanism can help establish it as a potential early marker for DN.

Non-Diabetic Renal Disease in Patients with Type 2 Diabetes Mellitus with Proteinuria

Background: Diabetes mellitus (DM) is the leading cause of end stage renal disease (ESRD) worldwide. Although DM with proteinuria is the ultimate result of diabetic nephropathy (DN), a wide spectrum of non-diabetic renal diseases (NDRD) can occur in such patients. Objective: To observe the frequency and histological pattern of NDRD in diabetic patients with proteinuria and to explore their association with clinical and laboratory parameters. Methods: This cross-sectional study was conducted in the Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from April 2016 to September 2017. In this study a total of 38 cases of DM with proteinuria (>1 gm/24-hour) were selected purposively. Renal biopsy was done in all patients. Based on histological findings they were categorized into two groups;Group 1 with NDRD and Group II with DN. Their clinical and laboratory parameters were analyzed and compared. Results: Among the total study subjects, 21 (55.3%) were male and 17 (44.7%) were female, mean (±SD) age 43.45 ± 9.99 years in the NDRD group and 41.57 ± 9.50 years in the DN group. Thirty one cases (81.6%) out of thirty eight had NDRD and seven (18.4%) cases had isolated DN;therefore more than two third cases had NDRD. Duration of DM was found to be significantly shorter (p = 0.004) in the NDRD group. Diabetic retinopathy was present in 12.9% cases in NDRD group vs. 57.1% cases in DN group (p = 0.025). Frequency of microscopic hematuria was significantly higher (90.3%) in NDRD patients (p = 0.002). Conclusion: The frequency of NDRD in type 2 diabetic patients other than diabetic nephropathy is relatively high. Membrano proliferative glomeru-lonephritis and membranous nephropathy are more common in NDRD. Absence of diabetic retinopathy, presence of hematuria and shorter duration of DM are markers associated with NDRD in type 2 DM, which are important indicators for renal biopsy in diabetic patients with proteinuria.

DN一号对糖尿病肾病的治疗作用

①目的 观察DN一号对糖尿病肾病的治疗效果 ,并对其作用机制进行探讨。②方法 采用链脲佐菌素 (STZ)单剂 (6 5mg/kg体质量 )腹腔注射方法建立糖尿病肾病大鼠模型 ,分为糖尿病肾病非治疗组 (Ⅱ组 )、糖尿病肾病治疗组 (Ⅲ组 )和正常对照组 (Ⅰ组 )。实验初始Ⅲ组大鼠每日用DN一号 5mL灌胃 ,Ⅱ组和Ⅰ组只灌入等量饮用水 ,连续 12周。定期观察大鼠体质量、肾质量、血糖、血脂、血肌酐、血内皮素 (ET)、转化生长因子 β1(TGF β1) ,2 4h尿微量清蛋白排泄率。留取大鼠模型肾组织进行光镜、电镜观察 ,并进行免疫组织学TGF β1,血管内皮细胞生长因子 (VEGF)的半定量分析。③结果 Ⅱ组大鼠第 8,12周时 2 4h尿蛋白排泄率、血脂、血糖、血ET ,TGF β1明显高于Ⅰ组大鼠 (F =4 .89～ 6 .2 5 ,q =2 .98～ 4 .72 ,P <0 .0 5 )。Ⅲ组大鼠DN一号治疗第 8,12周时 ,上述观察指标除血糖外均较Ⅱ组大鼠低 (F =4 .2 4～ 5 .98,q =3.2 0～ 4 .6 7,P <0 .0 5 )。Ⅲ组大鼠肾组织中TGF β1,VEGF表达亦较Ⅱ组低 (H =10 .2 4 ,11.4 8,t=2 .4 6 ,2 .38,P <0 .0 5 )。④结论 DN一号能减少糖尿病肾病的尿蛋白排泄 ,对糖尿病肾病的肾损伤有保护作用。DN一号对糖尿病肾病肾损伤保护作用与DN一号降低血ET ,TGF β1,VEGF的含量 ,降低?

桑叶多糖对DN大鼠肾脏CTGF表达的影响

目的:观察桑叶多糖(mulberry leaves polysaccharide,MLP)对糖尿病肾病(diabetic nephropathy,DN)大鼠肾组织结缔组织生长因子(connective tissue growth factor,CTGF)基因表达的影响,探讨MLP抗肾纤维化的作用机制。方法:将Wistar大鼠随机分为正常对照组、模型组、MLP高、中、低剂量治疗组。采用一次性腹腔注射STZ的方法建立DN大鼠模型。给予不同剂量MLP进行治疗8w后,检测24h UAlb和尿蛋白含量;通过RT-PCR法测定肾脏中CTGF mRNA表达。结果:MLP能显著降低DN大鼠24h UAlb和尿蛋白含量(P<0.01),下调CTGF mRNA表达(P<0.01)。结论:MLP可减少DN大鼠尿蛋白、24h UAlb,降低肾脏CTGF mRNA的表达。

外周血单核细胞DNMT1及血清IL-6在糖尿病肾脏病中的表达及意义

目的 探讨外周血单核细胞DNA甲基化转移酶1(DNMT1)及血清白介素-6(IL-6)在糖尿病肾脏病(DKD)中的表达及临床意义。方法 选取150例DKD患者(DKD组)及50例同期健康体检者(对照组)。比较2组IL-6、DNMT1、总胆固醇、三酰甘油、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血肌酐、空腹血糖、肾小球滤过率估计值(e GFR)、24 h尿白蛋白排泄率(24 h UAER)的差异。Pearson相关分析IL-6、DNMT1与其他临床指标的相关性。多因素Logistic回归分析DKD发生的影响因素。受试者工作特征(ROC)曲线分析24 h UAER、IL-6、DNMT1及联合检测对DKD的诊断价值。结果 与对照组比较,DKD组的空腹血糖、IL-6、DNMT1、血肌酐、24 h UAER、LDL-C、糖化血红蛋白水平升高,而eGFR、HDL-C水平降低(均P<0.05)。DKD组的IL-6与DNMT1呈正相关(r=0.560,P<0.05);且IL-6、DNMT1与24 h UAER呈正相关(r分别为0.551和0.570,P<0.05)。24 h UAER、IL-6及DNMT1升高是影响DKD发生的独立危险因素(P<0.05)。24 h UAER、IL-6、DNMT1联合检测诊断DKD的曲线下面积优于单一指标检测。结论 DKD患者DNMT1、IL-6水平升高,24 h UAER、DNMT1、IL-6联合检测可作为临床诊断DKD的良好指标。

DM2及DN患者尿足细胞膜表面糖蛋白检测的意义

目的:探讨2型糖尿病(type 2 diabetes mellitus,DM2)及其合并肾病(DN)尿足细胞膜表面糖蛋白(podocalyxin,PCX)浓度变化及临床意义。方法:根据尿白蛋白排泄率(UAER)将115例DM2患者分为单纯糖尿病(SDM组)44例、早期糖尿病肾病(EDN)41例和临床糖尿病肾病(CDN)30例;另选30例健康体检正常者作为正常对照(NC)组。采用酶联免疫吸附试验双抗体夹心法检测尿PCX。结果:SDM组、EDN组、CDN组尿PCX、高敏C反应蛋白(hs-CRP)较NC组升高(P<0.05),随病情加重,升高更为明显。尿PCX与hs-CRP高度相关(r=0.79,P<0.05)。DM2患者尿PCX水平随着尿白蛋白的增加而升高。结论:DM2患者尿PCX水平明显升高,可作为DN早期的敏感的诊断指标。

信息动机行为技巧模型对早期DN患者的干预研究

目的:探讨信息-动机-行为技巧模型对早期DN的影响。方法:将100例已确诊的早期DN患者随机分为对照组50例和研究组50例,对照组采用常规护理,研究组在常规护理的基础上,进行信息动机行为技巧模型干预。比较两组患者干预6个月、12个月的FPG、PG2 h、TG、TC、LDL-C、HDLC、Hb A1C、24 h UAER等生化指标及24 h UAER<30 mg的患者。结果:干预6个月、12个月后研究组的生化指标及24 h UAER<30 mg的患者例数较对照组改善更为显著,差异有统计学意义(P<0.05)。结论:信息-动机-行为技巧模型的干预可有效提高早期DN患者的治疗依从性,阻止或延缓病情的进展。

胰岛素强化降糖对早期DN患者血糖、肾功能的影响评价

目的:观察胰岛素强化降糖对早期糖尿病肾病(DN)患者血糖、肾功能的影响。方法:按随机数表法将66例早期DN患者分为胰岛素强化治疗组(研究组,n=33)和常规组(对照组,n=33)。观察两组患者治疗4周后血糖改善情况[空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)],于治疗前及治疗4周后检测两组患者肾功能相关指标[β_2-微球蛋白(β_2-MG)、尿白蛋白排泄率(UAER)、血肌酐(Scr)]、氧化应激指标[超氧化物歧化酶(SOD)、3-硝基酪氨酸(3-NT)、谷胱甘肽(GSH)]水平。结果:治疗后,两组FPG、2 h PBG、HbA1c、β_2-MG、UAER、Scr、3-NT水平均较治疗前降低,且研究组低于对照组,差异均有统计学意义(P<0.05);两组SOD、GSH水平均较治疗前升高,且研究组高于对照组,差异均有统计学意义(P<0.05)。结论:胰岛素强化治疗在控制血糖、改善患者肾功能和氧化应激等方面较常规口服降糖药更具优势。

DM2患者血糖波动与DN和TGF-β_1关系的探讨

目的:观察糖化血红蛋白(HbA1c)<7%的2型糖尿病(DM2)患者血糖波动与糖尿病肾病(DN)及转化生长因子-β1(TGF-β1)水平的关系。方法:50例DM2患者(无DN组25例,DN组25例)应用动态血糖监测系统(CGMS)连续监测血糖3d,计算平均血糖标准差(SDBG),平均血糖波动幅度(MAGE),最大血糖波动幅度(LAGE),曲线下面积(AUC),日间血糖绝对差(MODD)。采用酶联免疫吸附法(ELISA)测定血清TGF-β1水平。结果:DN组血清TGF-β1水平明显高于无DN组及对照组(P<0.05),DN组餐后2h血糖(2hPG)、SDBG、MAGE,LAGE,AUC,MODD均明显高于无DN组及对照组。结论:血糖波动可能通过升高肾间质纤维化指标TGF-β1水平而参与DN的发展。

DN一号对糖尿病肾病大鼠肾脏超微结构的影响

①目的 探讨DN一号 (主要成分为黄芪、党参、丹参、大黄合剂 )对糖尿病肾病大鼠肾脏超微结构的影响。②方法 建立糖尿病肾病大鼠动物模型 ,观察应用DN一号治疗 8周后大鼠肾脏超微结构的变化 ,并与未治疗组 (糖尿病肾病对照组 )、正常对照组进行比较。③结果 正常对照组大鼠肾脏超微结构均正常 ,足细胞、内皮细胞排列整齐 ,基膜厚度正常 ,屏障结构完整。糖尿病肾病对照组出现明显病变 ,系膜区明显增宽 ,足细胞足突融合、基膜增厚 ,屏障结构破坏 ,近曲小管上皮细胞凋亡明显。糖尿病肾病治疗组病变较糖尿病肾病对照组明显减轻。

丹参酮ⅡA磺酸钠对早期DN患者血清指标的影响分析

目的观察丹参酮ⅡA磺酸钠对早期糖尿病肾病(diabetic nephropathy,DN)患者血清指标的影响。方法纳入本院2019年8月—2020年1月收治的61例早期DN患者为研究对象,接受常规药物与丹参酮ⅡA磺酸钠治疗,比对分析患者治疗前后的血清指标。结果61例患者的空腹血糖(fasting plasma glucose,FPG)、血肌酐(serum creatinine,Scr)、甘油三酯(triglyceride,TG)水平均略有下降,但与治疗前比较,差异均无统计学意义(P> 0.05);而转化生长因子β1(transforming growth factor-β1,TGF-β1)与Ⅳ型胶原(collagenⅣ,CⅣ)水平则呈现为大幅下降,与治疗前比较,差异均有统计学意义(P<0.05)。结论早期DN患者临床经丹参酮ⅡA磺酸钠治疗后,其血清中的TGF-β1、CⅣ水平会大幅降低,有利于抑制患者病情,避免进一步发展给患者生命质量造成不良影响。